Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies

Acta Neurologica Scandinavica

Volumn 127, Issue 2, 2013, Pages e8-e12

  Constantinescu, R ^a   Andreasson, U ^a   Holmberg, B ^a   Zetterberg, H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Atypical parkinsonian disorders; Cerebrospinal fluid; Parkinson's disease; Serum; Urate

Indexed keywords

URATE;

ADULT; AGED; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; FEMALE; HUMAN; MALE; NOTE; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; SYNUCLEINOPATHY; TAUOPATHY;

EID: 84872672422     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12012     Document Type: Note

References (26)

1. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(10 Suppl 3): suppl32-7; discussion 7-9.
2. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996;144:480-4.
3. Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord 2007;22:1133-7.
4. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008;167:831-8.
5. De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H. Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum 2008;59:1549-54.
6. Ascherio A, LeWitt PA, Xu K et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-8.
7. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord 2008;14:576-8.
8. Maetzler W, Stapf AK, Schulte C et al. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-beta pathway. J Alzheimers Dis 2011;27:119-26.
9. Lee JE, Song SK, Sohn YH, Lee PH. Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 2011;26:1533-6.
10. Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord 2010;25:224-8.
11. Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain 2009;132(Pt 2):377-82.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
13. Gilman S, Low P, Quinn N et al. Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 1998;8:359-62.
14. Litvan I, Agid Y, Calne D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
15. Lang AE, Riley DE, Bergeron C. Cortico-basal ganglionic degeneration. In: Calne D, ed. Neurodegenerative diseases. Philadephia: WB Saunders; 1994;877-94.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
17. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5:75-86.
18. Litvan I. Recent advances in atypical parkinsonian disorders. Curr Opin Neurol 1999;12:441-6.
19. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003;18(Suppl 6):S2-12.
20. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 1998;13:70-7.
21. Constantinescu R, Romer M, Oakes D, Rosengren L, Kieburtz K. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord 2009;15:245-8.
22. Niklasson F, Hetta J, Degrell I. Hypoxanthine, xanthine, urate and creatinine concentration gradients in cerebrospinal fluid. Ups J Med Sci 1988;93:225-32.
23. O'Neill RD. Uric acid levels and dopamine transmission in rat striatum: diurnal changes and effects of drugs. Brain Res 1990;507:267-72.
24. Bierer DW, Quebbemann AJ. Effect of L-dopa on renal handling of uric acid. J Pharmacol Exp Ther 1982;223:55-9.
25. Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009;169:1064-9.
26. Winquist A, Steenland K, Shankar A. Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Mov Disord 2010;25:932-6.